WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies

November 1, 2017

London, UK, November 1 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces a research collaboration with global biopharmaceutical company AstraZeneca to validate a new in vitro research tool that enables the high throughput evaluation of multi-drug dosing regimens.

Under the collaboration, CN Bio will leverage intellectual property and technologies recently licensed by the company from Vanderbilt University, to mimic in vivo drug exposure in an in vitro system. The in vitro results will be compared with previous in vivo experiments conducted by AstraZeneca, to establish whether, in future, the use of certain animal studies can be reduced or replaced by these new in vitro capabilities.

Multi-drug therapies, treatments comprising two or more medicines, are increasingly being used to treat infectious disease, chronic diseases and cancer. Choosing which drugs to combine and the dosage frequency that will be most effective in treating disease while minimising any side effects can be extremely challenging. The high number of potential regimens that might be evaluated means that animal studies are not suited for such purposes.

Chief Executive Officer of CN Bio, Dr Emma Sceats said: “CN Bio is delighted to be collaborating with AstraZeneca to advance the development of this new in vitro research tool that could improve the chances that the best multi-drug regimens will reach patients.”

Dr Lorna Ewart, Head of Microphysiological Systems Centre of Excellence at AstraZeneca’s IMED Biotech Unit, said: “This new technology, which complements the work we are already doing with CN Bio in the area of Organs-on-Chips, has the potential to significantly improve on how we optimise drug scheduling and combination studies.”

–ENDS–

About CN Bio Innovations

CN Bio Innovations develops devices that boost the precision and speed of biological research. By predicting the effects chemical and biological substances will have on human organs, researchers can fast-track improvements in healthcare. In the past 4 years CN Bio has worked on more than 25 projects with pharmaceutical partners, using our Organs-on-Chips and related microfluidic devices to gather precise, human-relevant data.

CN Bio is backed by prestigious grant awards from sponsors including the US Department of Defence and Innovate UK. Spun out from the University of Oxford, the company is collaborating with and developing intellectual property from the Massachusetts Institute of Technology and Vanderbilt University.

Media enquiries:

Renate Krelle
[email protected]

Susan McQuillan
[email protected]
+44 (0) 1707 358739

Category iconPress releases

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023